Addex Therapeutics Ltd (SWX:ADXN)
0.0598
+0.0006 (1.01%)
Jun 27, 2025, 5:31 PM CET
Addex Therapeutics Revenue
Addex Therapeutics had revenue of 71.06K CHF in the quarter ending March 31, 2025, a decrease of -69.75%. This brings the company's revenue in the last twelve months to 246.19K, down -81.76% year-over-year. In the year 2024, Addex Therapeutics had annual revenue of 410.04K, down -74.64%.
Revenue (ttm)
246.19K
Revenue Growth
-81.76%
P/S Ratio
23.89
Revenue / Employee
123.09K
Employees
2
Market Cap
5.88M
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 410.04K | -1.21M | -74.64% |
Dec 31, 2023 | 1.62M | 172.23K | 11.92% |
Dec 31, 2022 | 1.44M | -1.71M | -54.18% |
Dec 31, 2021 | 3.15M | -725.84K | -18.71% |
Dec 31, 2020 | 3.88M | 1.05M | 36.89% |
Dec 31, 2019 | Pro | Pro | Pro |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Roche Holding AG | 62.40B |
Novartis AG | 47.05B |
Lonza Group AG | 6.57B |
Alcon | 8.77B |
Galderma Group AG | 4.02B |
Sandoz Group AG | 9.41B |
Straumann Holding AG | 2.50B |
Sonova Holding AG | 3.87B |
Addex Therapeutics News
- 3 days ago - Addex Shareholders Approve All Resolutions at Annual General Meeting - GlobeNewsWire
- 8 days ago - Earnings Scheduled For June 19, 2025 - Benzinga
- 9 days ago - Addex Therapeutics GAAP EPS of -CHF 0.01, income of CHF 0.07M - Seeking Alpha
- 9 days ago - Addex Therapeutics Reports Q1 2025 Financial Results and Provides Corporate Update - GlobeNewsWire
- 10 days ago - Addex Therapeutics to Release Q1 2025 Financial Results and Host Conference Call on June 19, 2025 - GlobeNewsWire
- 22 days ago - Addex GABAB PAM Candidate Demonstrates Robust Anti-Tussive Activity in Multiple Chronic Cough Preclinical Models - GlobeNewsWire
- 25 days ago - Addex Convenes Annual General Meeting 2025 - GlobeNewsWire
- 6 weeks ago - Addex Partner Indivior Advances GABAB Positive Allosteric Modulator Program Successfully Through IND Enabling Studies - GlobeNewsWire